HPTN 083 is a study being done to evaluate the efficacy of the long-acting injectable agent, cabotegravir (CAB LA), for...
A major disadvantage of giving SD NVP is the potential for maternal development of NVP resistance and additional resistance to...
IMPAACT P1026s, the predecessor of this study, was first approved in 2003. P1026s enrolled over 1000 pregnant/postpartum women,...
A5314 is a phase II randomized, double-blind, placebo-controlled 36-week trial that will examine the safety and efficacy of...
The study is being done with people who are taking their first anti-HIV drug regimen (including an Non-Nucleoside Reverse...
